$92.91 3.2%
GKOS Stock Price vs. AI Score
Data gathered: April 15

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Glaukos (GKOS)

Analysis generated September 30, 2024. Powered by Chat GPT.

Glaukos Corporation is a medical technology company focused on developing and commercializing novel ophthalmic products. The company's mission is to transform the treatment of glaucoma, one of the world's leading causes of blindness. Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) to deliver transformational outcomes for mild-to-moderate glaucoma patients. The company continues to advance a robust pipeline, including the expansion into new treatment modalities and further geographic markets.

Read full AI stock Analysis

Stock Alerts - Glaukos (GKOS)

company logo Glaukos | April 10
Price is down by -5.5% in the last 24h.
company logo Glaukos | April 9
Price is up by 7.7% in the last 24h.
company logo Glaukos | April 8
Price is down by -5.3% in the last 24h.
company logo Glaukos | April 7
Price is up by 5.7% in the last 24h.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.


Glaukos
Price $92.91
Target Price Sign up
Volume 712,540
Market Cap $5.1B
Year Range $82.27 - $161.22
Dividend Yield 0%
Analyst Rating 82% buy
Earnings Date April 30 '25
Industry Medical Devices

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q4 '24101M106M77M-34M-20M-0.400
Q3 '2497M87M74M-21M-18M-0.280
Q2 '2496M89M73M-51M-24M-0.520
Q1 '2481M88M65M-41M-31M-0.700
Q4 '2381M91M63M-37M-25M-0.630

Insider Transactions View All

Thurman Alex R. filed to sell 53,431 shares at $108.1.
March 27 '25
Thurman Alex R. filed to sell 53,462 shares at $107.4.
March 27 '25
Thurman Alex R. filed to sell 53,892 shares at $106.6.
March 27 '25
Foley Mark J filed to sell 54,249 shares at $120.7.
February 28 '25
Navratil Tomas filed to sell 72,437 shares at $147.1.
February 19 '25

What is the Market Cap of Glaukos?

The Market Cap of Glaukos is $5.1B.

When does Glaukos report earnings?

Glaukos will report its next earnings on April 30 '25.

What is the current stock price of Glaukos?

Currently, the price of one share of Glaukos stock is $92.91.

How can I analyze the GKOS stock price chart for investment decisions?

The GKOS stock price chart above provides a comprehensive visual representation of Glaukos' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Glaukos shares. Our platform offers an up-to-date GKOS stock price chart, along with technical data analysis and alternative data insights.

Does GKOS offer dividends to its shareholders?

As of our latest update, Glaukos (GKOS) does not offer dividends to its shareholders. Investors interested in Glaukos should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Glaukos?

Some of the similar stocks of Glaukos are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.